Browse LHX2

Summary
SymbolLHX2
NameLIM homeobox 2
Aliases LH-2; hLhx2; LIM HOX gene 2; LIM homeobox protein 2; homeobox protein LH-2; LIM/homeobox protein Lhx2
Chromosomal Location9q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00046 Homeobox domain
PF00412 LIM domain
Function

Acts as a transcriptional activator. Stimulates the promoter of the alpha-glycoprotein gene. Transcriptional regulatory protein involved in the control of cell differentiation in developing lymphoid and neural cell types (By similarity).

> Gene Ontology
 
Biological Process GO:0001654 eye development
GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0001843 neural tube closure
GO:0001942 hair follicle development
GO:0003002 regionalization
GO:0007163 establishment or maintenance of cell polarity
GO:0007389 pattern specification process
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0007423 sensory organ development
GO:0007498 mesoderm development
GO:0008544 epidermis development
GO:0009953 dorsal/ventral pattern formation
GO:0014020 primary neural tube formation
GO:0016049 cell growth
GO:0016331 morphogenesis of embryonic epithelium
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021772 olfactory bulb development
GO:0021871 forebrain regionalization
GO:0021915 neural tube development
GO:0021978 telencephalon regionalization
GO:0021987 cerebral cortex development
GO:0021988 olfactory lobe development
GO:0022404 molting cycle process
GO:0022405 hair cycle process
GO:0030011 maintenance of cell polarity
GO:0030900 forebrain development
GO:0035088 establishment or maintenance of apical/basal cell polarity
GO:0035090 maintenance of apical/basal cell polarity
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0042303 molting cycle
GO:0042633 hair cycle
GO:0043010 camera-type eye development
GO:0043392 negative regulation of DNA binding
GO:0043588 skin development
GO:0045197 establishment or maintenance of epithelial cell apical/basal polarity
GO:0045199 maintenance of epithelial cell apical/basal polarity
GO:0048588 developmental cell growth
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048675 axon extension
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051101 regulation of DNA binding
GO:0060041 retina development in camera-type eye
GO:0060560 developmental growth involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0060606 tube closure
GO:0061245 establishment or maintenance of bipolar cell polarity
GO:0061564 axon development
GO:0072175 epithelial tube formation
GO:0097485 neuron projection guidance
GO:0098773 skin epidermis development
GO:1990138 neuron projection extension
GO:2000677 regulation of transcription regulatory region DNA binding
GO:2000678 negative regulation of transcription regulatory region DNA binding
Molecular Function GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding
GO:0003682 chromatin binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolLHX2
NameLIM homeobox 2
Aliases LH-2; hLhx2; LIM HOX gene 2; LIM homeobox protein 2; homeobox protein LH-2; LIM/homeobox protein Lhx2
Chromosomal Location9q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LHX2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolLHX2
NameLIM homeobox 2
Aliases LH-2; hLhx2; LIM HOX gene 2; LIM homeobox protein 2; homeobox protein LH-2; LIM/homeobox protein Lhx2
Chromosomal Location9q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LHX2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLHX2
NameLIM homeobox 2
Aliases LH-2; hLhx2; LIM HOX gene 2; LIM homeobox protein 2; homeobox protein LH-2; LIM/homeobox protein Lhx2
Chromosomal Location9q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LHX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8770.0623
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.790.00559
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2380.757
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0260.966
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6840.47
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7910.495
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2680.678
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0210.982
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3640.706
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.60.631
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.2610.44
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.7190.0161
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LHX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLHX2
NameLIM homeobox 2
Aliases LH-2; hLhx2; LIM HOX gene 2; LIM homeobox protein 2; homeobox protein LH-2; LIM/homeobox protein Lhx2
Chromosomal Location9q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LHX2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLHX2
NameLIM homeobox 2
Aliases LH-2; hLhx2; LIM HOX gene 2; LIM homeobox protein 2; homeobox protein LH-2; LIM/homeobox protein Lhx2
Chromosomal Location9q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LHX2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LHX2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLHX2
NameLIM homeobox 2
Aliases LH-2; hLhx2; LIM HOX gene 2; LIM homeobox protein 2; homeobox protein LH-2; LIM/homeobox protein Lhx2
Chromosomal Location9q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LHX2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLHX2
NameLIM homeobox 2
Aliases LH-2; hLhx2; LIM HOX gene 2; LIM homeobox protein 2; homeobox protein LH-2; LIM/homeobox protein Lhx2
Chromosomal Location9q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LHX2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLHX2
NameLIM homeobox 2
Aliases LH-2; hLhx2; LIM HOX gene 2; LIM homeobox protein 2; homeobox protein LH-2; LIM/homeobox protein Lhx2
Chromosomal Location9q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LHX2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLHX2
NameLIM homeobox 2
Aliases LH-2; hLhx2; LIM HOX gene 2; LIM homeobox protein 2; homeobox protein LH-2; LIM/homeobox protein Lhx2
Chromosomal Location9q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LHX2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.